Alexandria Real Estate Equities, Inc. Highlights Its Role in Advancing Blood Cancer Innovation by Enabling Life-Changing Tenant R&D, Mission-Critical Philanthropic Initiatives and Strategic Investments

Alexandria Real Estate Equities, Inc. Highlights Its Role in Advancing Blood Cancer Innovation by Enabling Life-Changing Tenant R&D, Mission-Critical Philanthropic Initiatives and Strategic Investments

PASADENA, Calif., Sept. 4, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today recognizes Blood Cancer Awareness Month by highlighting its strategic investments and tenants developing life-saving therapies in hematology and oncology, as well as the company's longstanding mission-critical engagement with the nation's leading nonprofits focused on blood cancers. Blood cancers, also known as hematologic cancers, begin in blood-forming tissue, such as bone marrow, or in cells of the immune system. There are over 100 types of blood cancers, including leukemia, lymphoma and myeloma.

"According to Blood Cancer United, someone is diagnosed with leukemia, lymphoma or myeloma approximately every three minutes, representing 9.4% of all new cancers in the United States in 2025. And they remain a major cause of cancer mortality; someone in the U.S. dies from blood cancer approximately every nine minutes. There has been meaningful progress, and survival rates have improved substantially with over one million people in the U.S. living with or in remission from blood cancers, but continued investment and collaboration remain essential," said Peter Moglia, chief executive officer and chief investment officer of Alexandria Real Estate Equities, Inc. "Blood Cancer Awareness Month is more than a moment for recognition and reflection; it is a call to action to accelerate research, improve access and support patients and families. We are honored to partner with consequential nonprofit organizations focused on oncology and hematology, and deeply proud of Alexandria's mission-critical role in enabling our tenants and investments to develop life-changing treatments and cures."

Juno Therapeutics (Juno), Alexandria's longstanding tenant in Seattle, represents one of the defining success stories in blood cancer innovation. An early leader in CAR-T therapies, Juno helped advance the science behind Breyanzi®, one of the leading FDA-approved CAR-T cell therapies for relapsed or refractory B-cell blood cancers, with approvals across multiple lymphoma indications and marketed by Bristol Myers Squibb. Alexandria Venture Investments was also an early investor in Juno, which went public in 2014 at an IPO market capitalization of approximately $2.2 billion and was acquired by Celgene in 2018; Celgene was later acquired by Bristol Myers Squibb in 2019.

For over a decade, Alexandria has engaged with nonprofits advancing research, patient advocacy and access across oncology and hematology, including the Multiple Myeloma Research Foundation (MMRF), Blood Cancer United, the National Marrow Donor Program (NMDP), Alliance for Cancer Gene Therapy, Fred Hutch Cancer Center, Curebound, UCSD Health's Moores Cancer Center and Memorial Sloan Kettering Cancer Center. In 2012, Alexandria began its partnership with the MMRF, the largest nonprofit solely focused on accelerating a cure for multiple myeloma patients, with Joel Marcus, executive chairman and founder of Alexandria Real Estate Equities, Inc., serving on its board from 2014 to 2017. Alexandria is proud to support the MMRF at the nonprofit's Blood Cancer Awareness event at the Alexandria Center® for Life Science – New York City megacampus this month. Through Alexandria's corporate social responsibility initiatives, the company and its employees also support NMDP, formerly Be The Match, a global nonprofit leader in cell therapy that connects patients to life-saving donors and advances research to improve patient outcomes. Alexandria employees may use company-provided Volunteer Time Off to donate blood, platelets or bone marrow, and the company regularly coordinates blood drives across its collaborative campuses for both its employees and tenants.

About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle and New York City. For more information, please visit www.are.com.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding Alexandria's corporate responsibility initiatives, strategic investments, partnerships and support of charitable and community organizations; Alexandria's role in supporting tenants and companies in which it invests that are engaged in research and development in hematology and oncology; and the anticipated impact or benefits of these investments, partnerships and support, including the expected impact of the missions, programs and initiatives of the charitable and community organizations Alexandria supports. These forward-looking statements are based on Alexandria's present intent, beliefs, or expectations, but forward-looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements as a result of a variety of factors, including, without limitation, the risks and uncertainties detailed in its filings with the Securities and Exchange Commission. All forward-looking statements are made as of the date of this press release, and Alexandria assumes no obligation to update this information. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in Alexandria's forward-looking statements, and risks and uncertainties to Alexandria's business in general, please refer to Alexandria's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q.

CONTACT: Sara Cohen, Assistant Vice President – Capital Markets & Corporate Operations, (646) 799-2617, scohen@are.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-highlights-its-role-in-advancing-blood-cancer-innovation-by-enabling-life-changing-tenant-rd-mission-critical-philanthropic-initiatives-and-strategic-investments-302869252.html

SOURCE Alexandria Real Estate Equities, Inc.